HSCT Treatment Guides – The information you need to make the most important medical decision of your life.
HSCT — Haematopoietic Stem Cell Transplantation — is one of those treatments that can genuinely change the trajectory of an autoimmune condition. Not just manage it, not just slow it down, but actually stop it in its tracks. That’s something most conventional therapies simply can’t do.
But here’s the problem: for most patients, finding reliable information about HSCT is surprisingly hard. You end up wading through conflicting sources, half-explained medical jargon, and forum threads that raise more questions than they answer. And because HSCT sits at the intersection of haematology and neurology, even many specialists aren’t fully across the latest evidence.
That’s exactly why we put these guides together. The clinical team at HSCT Hospital India — a JCI-accredited centre that has focused deeply on haematopoietic transplantation for autoimmune conditions — wanted to give patients something better than what’s currently out there.
Each guide covers one specific condition: how HSCT works for it, who’s likely to benefit, what the clinical trials actually show, what the risks look like, what it costs, and the questions you should genuinely be asking your neurologist.
Because whether you’ve been managing Relapsing-remitting MS for years, recently received a CIDP diagnosis, finally got answers after a long road to a Small Fibre Neuropathy diagnosis, or are somewhere in the middle of figuring out Myasthenia Gravis — you deserve information that’s honest, clear, and actually useful. Not to push you toward a decision, but to help you make the right one, together with your medical team.
Choose your guide to HSCT
Each guide covers eligibility, clinical evidence, costs, risks, and step-by-step guidance on what to expect — written for patients and caregivers.
The most comprehensive resource on HSCT for MS available to patients in India and internationally. Covers the landmark MIST Trial, NEDA-3 outcomes, eligibility across all MS subtypes (RRMS, SPMS, PPMS, PRMS), the conditioning regimen used, and how HSCT compares to disease-modifying therapies including alemtuzumab and cladribine.
- Eligibility & EDSS criteria
- Clinical trial evidence (MIST, BEAT-MS)
- HSCT vs DMTs — outcomes comparison
- Cost, timeline & recovery
Small Fibre Neuropathy is one of the most underdiagnosed autoimmune nerve conditions — and for immune-mediated cases, HSCT is emerging as a viable path to long-term remission. This guide explains the diagnostic criteria (skin biopsy, IENF density), how to distinguish immune-mediated from genetic SFN, and the evolving evidence base for HSCT as a treatment option.
- Diagnosis — SFN testing & biopsy criteria
- Immune-mediated vs. genetic SFN
- HSCT candidacy for SFN patients
- Symptom management & recovery
Myasthenia Gravis disrupts the neuromuscular junction through autoantibody-mediated attack. For patients who have failed or become refractory to standard immunosuppression and thymectomy, HSCT offers the possibility of durable, antibody-driven remission. This guide covers the evidence, candidacy profile, and what patients with AChR+, MuSK+, and seronegative MG can realistically expect.
- MG severity classification (MGFA scale)
- Refractory MG & HSCT candidacy
- Role of thymectomy prior to HSCT
- Antibody dynamics post-transplant
CIDP is a chronic, relapsing autoimmune neuropathy that can be profoundly disabling. When IVIg, plasmapheresis, and corticosteroids provide only temporary relief, HSCT has shown the potential to deliver sustained remission by resetting the dysregulated immune system. This guide reviews the clinical case for HSCT in CIDP, including the PROPHET and AIRTIGHT trial data.
- CIDP diagnosis — EMG, CSF, nerve biopsy
- When standard therapy fails
- HSCT outcomes data for CIDP
- Distinguishing CIDP from MMN & GBS
